
Cydar Medical Ltd raises €10.5m in Series A financing
Besides Pembroke Venture Capital Trust as cornerstone investor with €3.7m (£3m), new investor Downing LLP and existing seed investors supported the...

ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

Ultra-processed foods increase risk for cancer
According to a long-term data from the UK biobank, high consumption of ultra-processed foods are linked to bad health outcomes such as diabetes,-...

Chong Kun Dang Pharm licences Synaffix ADC platform
Though the companies did not give any financial details, former licencing deals of Synaffix to global pharma companies such as Amgen or ranged...

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

Rewind Therapeutics extends Series A financing
The company, founded by CD3 (Leuven, Belgium) and Axxam S.p.A. (Milan), did not want to reveal the exact amount added to the €15.2m in its 2018...

Minaris and LIfT BioSciences collaborate in cell therapy development
LIfT BioSciences wants to start its first-in-human clinical trials with an allogeneic neutrophil progenitor-based cell therapy in first Quartal...